¹û¶³´«Ã½

Stocking fillers to share

John Baron reflects on aspects of the portfolios’ positioning after a good year

Getting the best out of biotech

Our diarist John Rosier thinks the biotech sector is being judged too harshly by investors

‘No deal’ upside

John Baron explains why the UK market looks good value regardless of a trade deal with the EU

Income opportunities from dividends

Phil Oakley outlines how to pick shares with high dividend growth potential

Building the world

With low yields on bonds, the hunt for income is challenging for investors. Could listed infrastructure provide a part of the answer?

The trust factor

Our private investor diarist, John Rosier, explains how investment trusts have been the biggest contributor to his returns this year

Momentum wins again

Our no-thought momentum portfolio has continued to beat the market – which is puzzling

The mechanics of diversification

John Baron explains how the portfolios reduce risk over time

Appetite for destruction

Are investors demonstrating more of a willingness to accept the risk of a crash?

Private investor's diary: Bagging biotech gains

Our private investor diarist John Rosier’s portfolio’s good run continued through August, helped along by a five-bagger biotech